GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (BSP:B1MR34) » Definitions » Cyclically Adjusted Price-to-FCF

Biomarin Pharmaceutical (BSP:B1MR34) Cyclically Adjusted Price-to-FCF : (As of Jun. 07, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Biomarin Pharmaceutical Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Biomarin Pharmaceutical Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Biomarin Pharmaceutical's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Cyclically Adjusted Price-to-FCF Chart

Biomarin Pharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Biomarin Pharmaceutical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Biomarin Pharmaceutical's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Biomarin Pharmaceutical's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomarin Pharmaceutical's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biomarin Pharmaceutical's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Biomarin Pharmaceutical's Cyclically Adjusted Price-to-FCF falls into.



Biomarin Pharmaceutical Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Biomarin Pharmaceutical's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Biomarin Pharmaceutical's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.161/131.7762*131.7762
=0.161

Current CPI (Mar. 2024) = 131.7762.

Biomarin Pharmaceutical Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -0.397 100.560 -0.520
201409 -0.247 100.428 -0.324
201412 -0.461 99.070 -0.613
201503 -1.810 99.621 -2.394
201506 -0.470 100.684 -0.615
201509 -0.574 100.392 -0.753
201512 -2.043 99.792 -2.698
201603 -2.480 100.470 -3.253
201606 -0.751 101.688 -0.973
201609 -0.354 101.861 -0.458
201612 -0.504 101.863 -0.652
201703 -1.354 102.862 -1.735
201706 -0.274 103.349 -0.349
201709 -0.037 104.136 -0.047
201712 -0.237 104.011 -0.300
201803 -0.676 105.290 -0.846
201806 -0.601 106.317 -0.745
201809 -0.031 106.507 -0.038
201812 0.079 105.998 0.098
201903 -0.919 107.251 -1.129
201906 -0.657 108.070 -0.801
201909 0.385 108.329 0.468
201912 -0.040 108.420 -0.049
202003 -0.773 108.902 -0.935
202006 -0.083 108.767 -0.101
202009 0.902 109.815 1.082
202012 -0.753 109.897 -0.903
202103 1.303 111.754 1.536
202106 0.767 114.631 0.882
202109 1.105 115.734 1.258
202112 -0.511 117.630 -0.572
202203 -0.972 121.301 -1.056
202206 0.380 125.017 0.401
202209 1.721 125.227 1.811
202212 -0.417 125.222 -0.439
202303 -1.322 127.348 -1.368
202306 0.589 128.729 0.603
202309 1.450 129.860 1.471
202312 -0.120 129.419 -0.122
202403 0.161 131.776 0.161

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Biomarin Pharmaceutical  (BSP:B1MR34) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Biomarin Pharmaceutical Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomarin Pharmaceutical (BSP:B1MR34) Business Description

Traded in Other Exchanges
Address
770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the U.S. in 2023.

Biomarin Pharmaceutical (BSP:B1MR34) Headlines

No Headlines